The Opioid Crisis Is Still Here And It's Evolving

Opioid addiction remains one of the most devastating public health crises in American history. According to the Centers for Disease Control and Prevention, approximately 105,000 people died from drug overdose in 2023, and nearly 80,000 of those deaths — about 76%, involved opioids. While 2024 brought the largest single-year percentage drop in overdose deaths in a decade, with preliminary data showing roughly 87,000 total drug overdose deaths between October 2023 and September 2024 — opioid-involved deaths remain above pre-pandemic levels, and the crisis is far from over.

Behind every statistic is a real person: a parent, a child, a coworker, a neighbor.

What makes this crisis particularly challenging is that it does not discriminate. Opioid use disorder (OUD) affects people of every age, income level, race, and geography, from rural Kansas to urban Ohio and beyond. And as treatment science evolves, so must the way healthcare providers, community partners, and treatment facilities collaborate to meet patients where they are.

That is exactly why Arista Recovery recently brought together a group of dedicated treatment professionals, physicians, and community partners for our Advances in Opioid Treatment Dinner, the first in a series of continuing education events designed to bridge clinical research with real-world practice.

Understanding Opioid Use Disorder: The Facts Every Provider Should Know

Before exploring where treatment is headed, it is important to understand the full scope and impact of opioid addiction today.

Prevalence and Reach

According to SAMHSA's 2023 National Survey on Drug Use and Health (NSDUH), 8.9 million people aged 12 or older misused opioids in the past year. Despite the scale of need, treatment access remains severely limited: among the 48.5 million Americans who had a substance use disorder in 2023, only 15.6% received any form of substance use treatment. The gap between need and access is not a clinical problem, it is a public health emergency.

A 2023 NIDA-supported study found that in 2021, an estimated 2.5 million people aged 18 and older had opioid use disorder in the past year, yet only 22% received medications for opioid use disorder (MOUD) — the most effective form of treatment.

The Economic Toll

The financial cost of the opioid epidemic is staggering. A 2025 White House Council of Economic Advisers analysis estimated that illicit opioids, primarily fentanyl, cost Americans $2.7 trillion in 2023 alone, equivalent to 9.7% of GDP. This figure accounts for lives lost, reduced quality of life for those living with OUD, healthcare expenses, lost productivity, and crime-related costs. Even by more conservative estimates, the U.S. Joint Economic Committee put the toll at nearly $1.5 trillion in 2020. The financial argument for expanding prevention and treatment access is as strong as the moral one.

The Fentanyl Factor

The opioid crisis has evolved through three distinct waves, each driven by different types of opioids. The current wave is dominated by illicitly manufactured fentanyl (IMF) a synthetic opioid roughly 50 times more potent than heroin. In 2023, synthetic opioids other than methadone, primarily fentanyl, were involved in approximately 72,776 overdose deaths. IMF is frequently found pressed into counterfeit pills or mixed into other drug supplies, often without users' knowledge, dramatically increasing overdose risk.

The good news: between 2023 and 2024, deaths involving synthetic opioids dropped by 35.6%, he largest single-category decline on record. This progress is real. But it depends on continued investment in evidence-based treatment.

The Neurobiological Reality of Addiction

One of the most important shifts in modern addiction medicine is understanding opioid use disorder not as a character flaw, but as a chronic brain disease. The National Institute on Drug Abuse (NIDA) defines addiction as a "chronic, relapsing disorder characterized by compulsive drug seeking and use despite adverse consequences," classifying it as a brain disorder because it involves functional changes to brain circuits involved in reward, stress, and self-control.

NIDA's treatment guidance is unambiguous: "Research shows that when treating addictions to opioids, medication should be the first line of treatment, usually combined with some form of behavioral therapy or counseling." When relapse occurs, it signals a need to adjust or re-engage treatment, not evidence that treatment has failed.

The Evolving Landscape of Medications for Opioid Use Disorder (MOUD)

One of the most important topics at our recent dinner event was the shifting landscape of medications for opioid use disorder, and how providers can best match patients to the right medication at the right time.

The Rise of Injectable Medications

Extended-release injectable medications have become increasingly central to OUD treatment protocols. Options like injectable extended-release naltrexone (Vivitrol) and extended-release injectable buprenorphine offer meaningful advantages for the right patients:

• Improved adherence: Monthly or twice-monthly injections eliminate the daily burden of oral medication compliance
• Reduced diversion risk: Injectable formulations cannot be shared or misused in the same way oral medications can
• Broader prescribing access: Following the 2023 elimination of the federal X-waiver requirement, any provider with Schedule III prescribing authority may now prescribe buprenorphine products dramatically expanding who can offer this treatment

At Arista Recovery, we offer treatment options to the patients we serve, and we have seen firsthand how this approach can be transformative.

The Continued Role of Methadone A Critical Nuance

One of the most important clinical points our speakers addressed at the dinner is one that often gets lost in conversations about "modern" treatment: the evolution of injectable medications does not, and should not, eliminate methadone from the treatment toolkit.

NIDA's own leadership has addressed this directly. In a 2024 Director's blog, NIDA stated that "in the fentanyl era, expanded access to methadone too is essential" and cited growing evidence that methadone may outperform buprenorphine for patients actively using fentanyl. A naturalistic follow-up study found that 53% of patients admitted to methadone treatment who tested positive for fentanyl at intake were still in treatment a year later, compared to 47% for buprenorphine-treated patients in a similar cohort.

Research across multiple peer-reviewed studies consistently supports methadone's effectiveness. A clinical study found that methadone and buprenorphine treatment are associated with 53% and 37% reductions in all-cause mortality, respectively, among patients with OUD compared to those receiving no MOUD. A separate Medicare-based NIDA study found that among patients who had experienced a nonfatal overdose, those who received methadone saw their odds of a subsequent lethal overdose drop by 58%.

For patients who continue to struggle after trying injectable therapies, methadone should be the next clinical step not a last resort or an afterthought. At Arista Recovery, our approach is built on this philosophy: matching each patient to the medication and level of care that gives them the best realistic chance at sustained recovery. No single medication is right for everyone, and the evidence demands we keep every effective option on the table.

Inside the CEU Dinner: Advances in Opioid Treatment

What We Hosted and Why It Matters

On the evening of our recent Advances in Opioid Treatment dinner, Arista Recovery brought together physicians, nurse practitioners, social workers, therapists, case managers, and community partners for a Continuing Education Unit (CEU) event designed to do something that doesn't happen nearly enough: put evidence-based opioid treatment science directly in the hands of the providers making daily clinical decisions.

The format was intentional. Rather than a lecture hall or a webinar, we hosted an intimate dinner, because the most productive professional conversations happen when people are in the same room, sharing a meal, and genuinely engaging with one another. Attendees left with CEU credit, but more importantly, they left with updated clinical knowledge, new referral relationships, and a stronger sense of community around a shared mission.

What Attendees Learned

The evening's featured presenter, Dr. Sethi, led an evidence-based deep dive into the current state of opioid use disorder treatment, covering topics that are directly relevant to the clinical decisions providers face every day:

The shift toward injectable MOUD Dr. Sethi walked through the clinical rationale for extended-release injectable medications like naltrexone and buprenorphine, discussing patient selection criteria, adherence advantages, and real-world outcomes data. Providers learned how to identify which patients are strong candidates for injectables and how to initiate treatment.

Why methadone still belongs in the conversation. One of the most clinically important takeaways of the evening was the discussion of methadone's continued and necessary role in OUD treatment. The group examined the evidence showing that for patients who do not achieve stability on injectable therapies, methadone is not a step backward. Providers left with a clearer framework for when to recommend methadone as the appropriate escalation of care, and how to connect patients to opioid treatment programs that provide it.

Navigating the continuum of care. Attendees discussed the full treatment pathway from detox through residential, PHP, IOP, and supportive housing, and the critical importance of warm handoffs between each level. The conversation addressed the gaps in care that most often lead to relapse: the period immediately following hospital discharge, the transition out of residential treatment, and the step-down from PHP to outpatient programming.

Arista Recovery's expanding services. Providers received a direct update on where Arista Recovery can serve as a referral partner today, including new programs in Kansas and Ohio as well as our new Primary Mental Health Residential program.

The Value of Continued Addiction in Addiction Medicine

Continuing education in addiction medicine is not simply a professional expectation — it is a clinical necessity. The science surrounding opioid use disorder treatment continues to evolve rapidly, alongside changing regulations, emerging research, and shifts in the substance use landscape driven by illicitly manufactured fentanyl and polysubstance use. Providers relying on outdated information may unintentionally miss opportunities to deliver the most effective, evidence-based care.

Organizations such as Substance Abuse and Mental Health Services Administration and National Institute on Drug Abuse continue to emphasize the importance of ongoing provider education to help close the gap between individuals who need treatment and those who actually receive it. Educational initiatives and professional learning opportunities, such as those hosted by Arista Recovery, serve as one practical way to strengthen provider knowledge, expand access to evidence-based care, and improve outcomes for individuals and families affected by substance use disorders,  one provider at a time.

Arista Recovery's Commitment to Ongoing Provider Education

The Advances in Opioid Treatment Dinner was not a one-time event, it was the launch of an ongoing educational series Arista Recovery is committed to hosting throughout 2026 and beyond. Our goal is straightforward: to regularly bring together the treatment professionals in our communities, keep them current on the latest clinical evidence, strengthen local referral networks, and ultimately ensure that more patients find their way to the right level of care.

Future events will continue to offer CEU credit, feature expert clinical speakers, and create space for the kind of peer-to-peer conversation that changes how providers approach their work.

If you are a physician, APRN, therapist, social worker, case manager, or other healthcare professional in the Kansas or Ohio area and would like to be notified about upcoming CEU events hosted by Arista Recovery, we encourage you to reach out and get on our list. These events are intimate, and built around the clinical conversations that matter most to you and your patients.

Arista Recovery: Expanding Access Across the Continuum of Care

Effective opioid treatment requires the ability to meet patients at any stage of their recovery journey and to step them appropriately through levels of clinical support. At Arista Recovery, expanding that continuum has been our driving focus.

Levels of Care We Provide

Medical Detoxification (Detox) Safe, supervised withdrawal management with 24/7 medical oversight. Detox is the critical first step for patients who are physically dependent on opioids and need a medically managed transition before engaging in further programming.

Residential Treatment Immersive, around-the-clock care in a structured therapeutic environment. Our residential programs address not just addiction, but the underlying mental health, trauma, and behavioral patterns that sustain it.

Partial Hospitalization Program (PHP) A step down from residential, PHP offers intensive structured treatment during the day while patients begin to reintegrate into daily life, multiple hours of clinical programming five to seven days per week.

Intensive Outpatient Program (IOP) IOP provides continued therapeutic support, group therapy, individual counseling, medication management, while allowing patients to live at home or in a sober living environment. This level is ideal for patients who have achieved initial stability and are building long-term recovery skills.

Primary Mental Health Residential Because opioid addiction and co-occurring mental health disorders are so frequently intertwined, we have launched a dedicated Primary Mental Health Residential Program in Kansas for patients whose mental health needs are the primary driver of their substance use.

Where Arista Recovery Is Growing

Arista Kansas

Arista Recovery has deep roots in Kansas and continues to strengthen and expand its programs statewide. Our Paola,Kansas location offer detox, residential, PHP, and IOP for opioid addiction, and our Overland Park PHP program and intensive outpatient program is growing rapidly to meet regional demand.

Arista Ohio

We are proud to announce our expansion into Ohio, where we now actively treat patients with both commercial insurance and Medicaid. Expanding Medicaid access is both a clinical and ethical priority. Ensuring Medicaid patients in Ohio receive the same quality of care as commercially insured patients is a commitment we take seriously.

The Path Forward with Arista Recovery

The opioid epidemic will not be solved by any single treatment facility, any single medication, or any single clinician. It requires a coordinated, compassionate, and continuously evolving response, one in which community providers, treatment professionals, and patients are genuine partners in care.

Arista Recovery's Advances in Opioid Treatment Dinner was a meaningful step in that direction. We are committed to continuing these conversations, deepening these partnerships, and ensuring that patients across Kansas and Ohio can access the right care at the right time.

If you are a healthcare provider looking for a trusted referral partner for patients struggling with opioid use disorder, we welcome your reach-out.

If you or a loved one is struggling with opioid addiction, know that evidence-based, compassionate treatment is available, and that recovery is possible. Reach out to Arista today for a free assessment or to learn more about our opioid use disorder treatment programs.

Stay tuned for details on our upcoming continuing education events for healthcare providers.

References

1. Centers for Disease Control and Prevention. Understanding the Opioid Overdose Epidemic. 2024. https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html
2. Centers for Disease Control and Prevention. CDC Reports Nearly 24% Decline in U.S. Drug Overdose Deaths. Press Release, February 2025. https://www.cdc.gov/media/releases/2025/2025-cdc-reports-decline-in-us-drug-overdose-deaths.html
   CDC National Center for Health Statistics. Drug Overdose Deaths in the United States, 2023–2024. NCHS Data Brief No. 549. December 2024. https://www.cdc.gov/nchs/products/databriefs/db549.htm
3. Substance Abuse and Mental Health Services Administration. Highlights for the 2023 National Survey on Drug Use and Health. 2024. https://www.samhsa.gov/data/sites/default/files/NSDUH%202023%20Annual%20Release/2023-nsduh-main-highlights.pdf
4. National Institute on Drug Abuse. Only 1 in 5 U.S. Adults with Opioid Use Disorder Received Medications to Treat It in 2021. August 2023. https://nida.nih.gov/news-events/news-releases/2023/08/only-1-in-5-us-adults-with-opioid-use-disorder-received-medications-to-treat-it-in-2021
   National Institute on Drug Abuse. Drug Overdose Deaths: Facts and Figures. August 2024. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates
5. National Institute on Drug Abuse. Drug Misuse and Addiction. Updated 2025. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/drug-misuse-addiction
   National Institute on Drug Abuse. Treatment and Recovery. Updated 2025. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery
6. National Institute on Drug Abuse. To Address the Fentanyl Crisis, Greater Access to Methadone Is Needed. Director's Blog, July 2024. https://nida.nih.gov/about-nida/noras-blog/2024/07/to-address-the-fentanyl-crisis-greater-access-to-methadone-is-needed
7. National Institute on Drug Abuse. Federal Study Examines Care Following Nonfatal Overdose Among Medicare Beneficiaries. June 2024. https://nida.nih.gov/news-events/news-releases/2024/06/federal-study-examines-care-following-nonfatal-overdose-among-medicare-beneficiaries
8. Blackwood, C.A. & Cadet, J.L. The Molecular Neurobiology and Neuropathology of Opioid Use Disorder. Current Research in Neurobiology, NIH/NIDA. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC9090195
9. White House Council of Economic Advisers. The Staggering Cost of the Illicit Opioid Epidemic in the United States. March 2025. https://www.whitehouse.gov/releases/2025/03/the-staggering-cost-of-the-illicit-opioid-epidemic-in-the-united-states/
10. U.S. Joint Economic Committee. The Economic Toll of the Opioid Crisis Reached Nearly $1.5 Trillion in 2020. 2022. https://www.jec.senate.gov/public/index.cfm/democrats/2022/9/the-economic-toll-of-the-opioid-crisis-reached-nearly-1-5-trillion-in-2020